Disclosed positions
Reported underlying-position values for 2024-09-30, publicly available 2024-11-15. Put/call values are not option premiums; this subset is not a complete portfolio allocation. Exact issuer, class and unit remain in the table. Showing the first 10 of 50 recorded values; the complete table remains available below.
Inspect all 50 displayed rows: Disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| SPDR SER TR | XBI | S&P BIOTECH | $29,640,000 | 300,000 | SH | Put |
| BIOHAVEN LTD | Unresolved | CALL | $17,428,437 | 348,778 | SH | None |
| SAREPTA THERAPEUTICS INC | SRPT | COM | $14,986,800 | 120,000 | SH | None |
| NOVO-NORDISK A S | NVO | ADR | $13,097,700 | 110,000 | SH | None |
| BLUEPRINT MEDICINES CORP | BPMC | COM | $12,950,000 | 140,000 | SH | None |
| AXSOME THERAPEUTICS INC | AXSM | COM | $12,132,450 | 135,000 | SH | None |
| TARSUS PHARMACEUTICALS INC | TARS | COM | $11,511,500 | 350,000 | SH | None |
| PERSPECTIVE THERAPEUTICS INC | CATX | COM NEW | $10,012,500 | 750,000 | SH | None |
| CG ONCOLOGY INC | CGON | COM | $9,432,500 | 250,000 | SH | None |
| ROIVANT SCIENCES LTD | ROIV | SHS | $9,232,000 | 800,000 | SH | None |
| VAXCYTE INC | PCVX | COM | $9,141,600 | 80,000 | SH | None |
| VIKING THERAPEUTICS INC | VKTX | COM | $8,863,400 | 140,000 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $8,662,500 | 450,000 | SH | None |
| JANUX THERAPEUTICS INC | JANX | COM | $8,631,700 | 190,000 | SH | None |
| ASCENDIS PHARMA A/S | ASND | SPONSORED ADR | $7,838,775 | 52,500 | SH | None |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $7,665,000 | 150,000 | SH | None |
| SOLENO THERAPEUTICS INC | SLNO | COM | $7,573,500 | 150,000 | SH | None |
| TG THERAPEUTICS INC | TGTX | COM | $7,250,900 | 310,000 | SH | None |
| REZOLUTE INC | RZLT | COM NEW | $7,153,726 | 1,474,995 | SH | None |
| PHATHOM PHARMACEUTICALS INC | PHAT | COM | $6,780,000 | 375,000 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $6,474,483 | 128,411 | SH | None |
| OLEMA PHARMACEUTICALS INC | OLMA | COM | $6,387,900 | 535,000 | SH | None |
| IMMUNOVANT INC | IMVT | COM | $6,129,650 | 215,000 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $5,475,000 | 75,000 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $5,204,550 | 195,000 | SH | None |
| REPLIMUNE GROUP INC | REPL | COM | $4,932,000 | 450,000 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $4,538,600 | 220,000 | SH | Put |
| BRIDGEBIO PHARMA INC | BBIO | COM | $4,455,500 | 175,000 | SH | None |
| TAYSHA GENE THERAPIES INC | TSHA | COM SHS | $4,321,500 | 2,150,000 | SH | None |
| RHYTHM PHARMACEUTICALS INC | RYTM | COM | $4,130,532 | 78,842 | SH | None |
| ANNEXON INC | ANNX | COM | $3,848,000 | 650,000 | SH | None |
| KORRO BIO INC | KRRO | COM | $3,676,200 | 110,000 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $3,650,000 | 50,000 | SH | Call |
| DYNE THERAPEUTICS INC | DYN | COM | $3,592,000 | 100,000 | SH | None |
| ARVINAS INC | ARVN | COM | $3,571,350 | 145,000 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $3,300,800 | 160,000 | SH | None |
| HELIX ACQUISITION CORP II | Unresolved | CL A ORD SHS | $3,134,988 | 300,000 | SH | None |
| NUVATION BIO INC | NUVB | COM CL A | $3,091,500 | 1,350,000 | SH | None |
| SAVARA INC | SVRA | COM | $3,074,000 | 725,000 | SH | None |
| TENAYA THERAPEUTICS INC | TNYA | COM | $2,895,000 | 1,500,000 | SH | None |
| REGENXBIO INC | RGNX | COM | $2,779,850 | 265,000 | SH | None |
| CORVUS PHARMACEUTICALS INC | CRVS | COM | $2,640,000 | 500,000 | SH | None |
| ABSCI CORPORATION | ABSI | COM | $2,101,000 | 550,000 | SH | None |
| NEUROGENE INC | NGNE | COM | $2,098,000 | 50,000 | SH | None |
| CAPRICOR THERAPEUTICS INC | CAPR | COM NEW | $1,901,250 | 125,000 | SH | None |
| APELLIS PHARMACEUTICALS INC | APLS | COM | $1,874,600 | 65,000 | SH | None |
| SUMMIT THERAPEUTICS INC | SMMT | COM | $1,861,500 | 85,000 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $1,764,600 | 60,000 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $1,706,250 | 75,000 | SH | None |
| PROQR THRAPEUTICS N V | PRQR | SHS EURO | $1,615,614 | 887,700 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
Read one actual disclosure before using it
Show the table · 1 row, 7 columns
Scroll sideways to compare all columns. Select a heading to sort.
| SPDR SER TR | XBI | S&P BIOTECH | $29,640,000 | 300,000 | SH | Put |
No matching rows. Clear the filter to see all records.
First displayed source row from Disclosed positions. The full bounded history and coverage notes remain below.
The displayed observation date is 2024-09-30 and its public availability date is 2024-11-15. Subtracting those calendar dates gives 46 days of disclosure lag. Historical public research can use the record from the availability date, rather than backdating knowledge to the observation date. The calendar-day difference does not assert an intraday publication time.
Read the amount together with its Unit and Option columns. A reported put or call position is not an option premium paid, and a quarterly holding is not a purchase made on its public filing date. Check every accession in the effective amendment lineage below: a retained holding can originate in an earlier filing rather than the latest linked amendment.
Open the linked original receipts to verify the row, then inspect a second record before drawing a pattern. This public filing observation supplies source evidence, not a completed copy-trading return.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 2 positions lack a resolved ticker and 3 positions are put or call entries.
The displayed holdings combine the effective filing versions listed here. The latest receipt linked below identifies the current projection version; it is not proof that every retained holding originated in that latest amendment. Inspect all effective accessions when verifying a position's source.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Show the table · 1 row, 2 columns
| Effective SEC accession | Role in this view |
|---|---|
| 0001420506-24-002434 | Latest effective version |
No matching rows. Clear the filter to see all records.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.